BREAKING: Trump CRACKING DOWN – It’s Happening
BREAKING: Church Shooting – Please Pray…
BREAKING: Church Bell SILENCED – Pure Evil
BREAKING: Ten Commandments Bombshell – It’s Happening
Daily Christian News
Affiliated with American Digest Media
539 W. Commerce St #1610
Dallas, TX 75208 DCN1
United States
This email was sent to PETER.HOVIS@GMAIL.COM
why did I get this?unsubscribe from this listupdate subscription preferences
Daily Christian News · 1328 Highpoint Way · Roanoke, TX 76262 · USA
When it comes to books, we can’t pick favorites—but you can. So here are some of the most popular books this week selected by readers like you:40 Questions about Angels, Demons, and Spiritual Warfare (40 Questions Series)
🔥 38,553 bought this week
In 40 Questions About Angels, Demons, and Spiritual Warfare, John Gilhooly provides a biblical and balanced perspective on the many issues surrounding the spiritual realm.
Your price: $21.99
Learn moreEl Reino de los Cielos
🌟 519 bought this week
“Todo predicador y maestro debe enfrentarse a la pregunta: ¿qué es el evangelio? Jesús comenzó su ministerio proclamando la llegada del Reino de los Cielos”, comienza el ministro wesleyano H.
Your price: $11.99
Learn moreTo Save Sinners: A Critical Evaluation of the Multiple Intentions View of the Atonement
⭐ 222 bought this week
The atoning work of the Lord Jesus Christ on the cross stands as the very epicenter of Christianity, the very heart of the gospel.
Regular Price: $49.00
20% off
Your price: $38.99
⭐ 190 bought this week
Every effective preacher needs tools to craft faithful, text-driven sermons.
Regular Price: $34.99
14% off
Your price: $29.99
Learn moreLa Centralidad del Evangelio: Recuperando lo esencial de la fe
⭐ 165 bought this week
¡Es hora de recuperar el núcleo de nuestras creencias! Aspectos importantes del cristianismo corren el peligro de enturbiarse o perderse a medida que el relativismo se arraiga en nuestras iglesias hoy.
Your price: $11.99
Join the Newly Revamped Logos Community
Find help and study ideas from thousands of Logos users.Join now →
You are subscribed to receive emails from Logos.
You can manage your preferences or unsubscribe at any time.
315 Prospect St, #759 Bellingham, WA 98225 US
Contact Us Privacy Policy
© 2025 Faithlife. All rights reserved.
BREAKING: Pope Leo Steps In – Conservatives Cheering
IT’S FINALLY OVER: Huge Pro-Life WIN – Trump Orders…
BREAKING: Trump Brings IT BACK – Godless Liberals Seethe
BREAKING: Amazing! Nuns Win Their Case Against…
Daily Christian News
Affiliated with American Digest Media
539 W. Commerce St #1610
Dallas, TX 75208 DCN2
United States
This email was sent to PETER.HOVIS@GMAIL.COM
why did I get this?unsubscribe from this listupdate subscription preferences
Daily Christian News · 1328 Highpoint Way · Roanoke, TX 76262 · USA
Conor Orr
The former Packers and Cowboys coach has a history of success similar to that of one of the coaches in the AFC championship.
Matt Verderame
Seattle and New England would set up a Super Bowl XLIX rematch if this weekend’s games play out as expected.
Theo Lloyd-Hughes
In its first match of 2026, the U.S. grew into a game that showed rust and quality in almost equal measure.
Get the print edition of Sports Illustrated delivered to your door.
Stay ahead of the game—sign up for all of SI’s newsletters, from golf and soccer to MMQB, and never miss a moment.
We may receive compensation for some links to products and services included in this email.
Sports Publishing Solutions Inc.
625 Broadway, 10th floor
New York, NY. 10012
You are receiving this email because you are subscribed to the Sports Illustrated newsletter.
You can unsubscribe here .
Privacy Policy – Terms & Conditions
© 2026 Sports Publishing Solutions Inc. All rights reserved.
SPORTS ILLUSTRATED IS A REGISTERED TRADEMARK OF ABG-SI LLC.
All betting and gambling content included in the Sports Illustrated newsletter is intended for individuals 21+ (18+ in DC, KY, NH, RI, and WY). Betting and gambling content, including picks and predictions, are based on individual commentators’ opinions and we do not guarantee any success or profits. If you or someone you know has a gambling problem, crisis counseling and referral services can be accessed by calling 1-800-GAMBLER or texting 800GAM.
Click this link to view the newsletter in your browser.
Every day offers a new chance to grow—so explore stories filled with real-life inspiration, practical wisdom, and ideas that fuel your next step forward. Discover uplifting content curated to support your personal growth, and join thousands of readers who visit our site daily for motivation, insight, and a positive boost.
“The final week of a month is not a deadline—it’s an opportunity to honor how far you’ve come and to keep moving forward.”
You’re nearing the end of January, and whether or not you’ve accomplished everything you hoped, you’ve made it this far. That alone deserves recognition. This week, focus less on what’s left undone and more on what you’ve already achieved. You’re building a life, not racing toward a finish line. Keep going with patience and self-compassion.MORE INSPIRATION
You’re always one blessing away from a brighter day… and a bigger life. May these stories, affirmations, prayers, and insights lift your spirits and inspire you to lift others.
Go forth and be blessed!GET BLESSINGS
🕊️
Blessings. Healing. Faith. TodaysBlessing. Please note, this is a postal address only.
9830 North Magnolia Ave Unit #503 Santee, CA 92071
Please, Unsubscribe Here to stop receiving these emails
Dehydration is an ancient art, but it has to be done correctly.
If you get the temperature wrong, or if you slice the meat too thick, you risk something called “Case Hardening.”
This is when the outside of the food dries too fast, trapping moisture inside. To the naked eye, it looks dry. But inside? Mold and bacteria are growing.
Don’t risk your family’s health.
I wrote “The No-Fridge Survival Cookbook” to give you the exact safety protocols for dehydrating meat, poultry, and vegetables.
I want to send you a physical copy for free.
In Chapter 2, I cover:
Knowledge is safety. Before you run another cycle on your dehydrator, get this book.
Click here to get it shipped to your door.
Stay safe,
Jill
You Might Like
In the vast landscape of news and media, it’s essential that we don’t let important conservative stories slip through the cracks. Our mission is to provide comprehensive coverage that champions our shared values.
Did we overlook a story or event that you believe deserves attention?
👉 Hit ‘Reply’ and let us know. Your insights ensure that our community remains informed and that every conservative voice gets the platform it deserves.
Together, we can ensure that no story goes untold and that our conservative principles are represented in every conversation.
Thank you for being an active participant in our mission.
CLICK HERE TO REMOVE YOURSELF FROM OUR LIST
Material Connection Disclosure: Unless otherwise expressly stated, you should assume that all references to products and services on this website are made because material connections exist between the sender of this email and the providers of the mentioned products and services.Anti Spam PolicyPrivacy PolicyTerms of UseCompensation Disclosure
Patriot Powered Publishing | 5613 SE 67th St OK 73135
You are Subscribed Under Email: [Email]
Unsubscribe | Report Spam | View In Browser
The following may contain promotional content from our paid sponsors.
Dehydration is an ancient art, but it has to be done correctly.
If you get the temperature wrong, or if you slice the meat too thick, you risk something called “Case Hardening.”
This is when the outside of the food dries too fast, trapping moisture inside. To the naked eye, it looks dry. But inside? Mold and bacteria are growing.
Don’t risk your family’s health.
I wrote “The No-Fridge Survival Cookbook” to give you the exact safety protocols for dehydrating meat, poultry, and vegetables.
I want to send you a physical copy for free.
In Chapter 2, I cover:
Knowledge is safety. Before you run another cycle on your dehydrator, get this book.
Click here to get it shipped to your door.
Stay safe,
Jill
You Might Like
In the vast landscape of news and media, it’s essential that we don’t let important conservative stories slip through the cracks. Our mission is to provide comprehensive coverage that champions our shared values.
Did we overlook a story or event that you believe deserves attention?
👉 Hit ‘Reply’ and let us know. Your insights ensure that our community remains informed and that every conservative voice gets the platform it deserves.
Together, we can ensure that no story goes untold and that our conservative principles are represented in every conversation.
Thank you for being an active participant in our mission.
CLICK HERE TO REMOVE YOURSELF FROM OUR LIST
Material Connection Disclosure: Unless otherwise expressly stated, you should assume that all references to products and services on this website are made because material connections exist between the sender of this email and the providers of the mentioned products and services.Anti Spam PolicyPrivacy PolicyTerms of UseCompensation Disclosure
Patriot Powered Publishing | 5613 SE 67th St OK 73135
You are Subscribed Under Email: [Email]
Breaking News from Newsmax.com
• Paralyzing Winter Storms Put Big Chill on US Economy
Special: The #1 Underlying Cause of Today’s Deadliest Diseases
Why Are Chronic Diseases Skyrocketing?
The Hidden Culprit Behind America’s Health Crisis
Dear Reader,
Despite remarkable advancements in medical science, chronic diseases like heart disease, cancer, diabetes, and Alzheimer’s continue to skyrocket. So, what’s the real cause behind this alarming trend?
The answer is a stealthy villain that’s been quietly damaging our health for years: chronic inflammation.
A Vital Warning From Dr. Russell Blaylock, M.D.
Dr. Russell Blaylock, a world-renowned neurosurgeon and leading health expert, is exposing the shocking truth behind inflammation’s destructive role in some of today’s most deadly diseases. Fueled by common foods, hidden toxins, and environmental factors, inflammation is silently wreaking havoc on your body — leading to debilitating and life-threatening conditions.
Why You Should Be Alarmed
Despite breakthroughs and billion-dollar medications, people are still getting sicker. The underlying cause? Inflammatory sugars, harmful oils, chemicals, and GMOs hiding in everyday foods are keeping us ill.
But There’s a Solution!
Dr. Blaylock has developed an Anti-Inflammation Program packed with proven strategies to stop, reverse, and prevent inflammation — empowering you to live healthier and avoid these devastating diseases. With his program, you’ll discover how to:
Exclusive Free Offer — Get Healthy Today
For a limited time, you can access Dr. Blaylock’s complete Anti-Inflammation Program — a $140 value — for FREE! This includes critical reports on reversing inflammation, debunking harmful medical myths, and preventing diseases naturally.
CLAIM YOUR FREE HEALTH KIT NOW! Click Here to reverse inflammation and protect your body from deadly diseases!
LAST CHANCE: Get Your $140 Anti-Inflammation Kit FREE
Click Here to Secure Yours NOW!
This email is never sent unsolicited. You have received this Newsmax email because you subscribed to it or someone forwarded it to you. To opt out, see the links below.
Remove your email address from our list or modifyyour profile. We respect your right to privacy. Viewour policy.
This email was sent by:
Newsmax.com
362 N. Haverhill Road
West Palm Beach, FL 33415 USA
DM912074
010102nzny3c
Your recap for January 26, 2026 Top stories for youWhy Is GameStop (GME) Stock Rocketing Higher TodayWhy Cisco (CSCO) Stock Is Trading Up TodayWhy Seagate Technology (STX) Stock Is Up TodayMichael Burry, an Early GameStop Buyer, Is Back Hyping the StockDear Seagate Technology Fans, Mark Your Calendars for January 27View more storiesMy portfolio highlightsDay Change +0.39%Top gainersGMEGameStop24.01
+4.44%STXSeagate Technology358.29
+3.52%CSCOCisco Systems77.01
+3.24%Top losersCLFCleveland-Cliffs14.02
-7.09%WENThe Wendy’s Company8.08
-4.04%GCOGenesco32.76
-3.45%Most activesGMEGameStop24.01
+4.44%CLFCleveland-Cliffs14.02
-7.09%XOMExxon Mobil134.84
-0.1%View your portfoliosUS market highlightsS&P 500
+0.63%Dow 30
+0.73%Nasdaq
+0.58%Russell 2000
-0.28%Crude Oil
-0.82%Top gainersPTRN
Pattern Group Inc…16.18
+13.38%NET
Cloudflare, Inc.192.99
+11.27%ZM
Zoom Communicatio…94.5
+10.17%Top losersEMAT
Evolution Metals …7.21
-24.48%TMC
TMC the metals co…7.69
-18.55%RVMD
Revolution Medici…98.26
-16.5%Most activesINTC
Intel Corporation42.4
-5.95%USAR
USA Rare Earth, Inc.26.3
+6.2%NVDA
NVIDIA Corporation186.41
-0.68%Yahoo Finance App: Portfolio performance, news and alerts, stock data and all you need in a finance app. Download now.
Privacy Policy | Customer Support | Unsubscribe
©2026 Yahoo Inc. All Rights Reserved.
770 Broadway, New York, NY 10003
Editor’s Note: Last week, we had a fantastic session with Jon Najarian and Senior Analyst Chris Johnson, and this week Jon is coming back for another event with our own Nate Bear and Ryan Fitzwater.
This free masterclass is a unique opportunity to get FREE trade ideas and perspectives from both a member of the Options Trading Hall of Fame and every day trader who grew his wealth from his home office.
It starts on Wednesday, Jan. 28 at 2 p.m. ETin the MTALive chatroom.
– Stephen Prior, Publisher
Last week was a week.
Between the Greenland situation and the WEF meeting, I was feeling decision fatigue on Friday.
As a trader, when mental power starts slowing down, you have to keep your wits.
Patience becomes key.
And one of the lotto setups I was waiting on was Carvana (CVNA).
The chart looked incredible.
It was nearing all-time highs at $485 with an A+ squeeze.
Given this momentum potential, I took out a lotto trade and 1 butterfly trade targeting $500 on Thursday.
I paid .39 for this butterfly trade on CVNA.
By the end of the trading day, it was closing at $2.13.
So I closed the first lotto for a 400% gain, but I wasn’t done yet.
Although the lotto was closed, I held on to the butterfly trade for a few reasons…
One, I thought CVNA had more room to run.
Two, given that CVNA options were super cheap the next day, I could capture that continued momentum without as much risk.
All I needed was a little push into all-time highs.
So I added to the lotto on Friday.
Then in less than 1 hour, that momentum shift came.
CVNA moved up into all-time highs, and I closed the lotto trade for a 370% winner.
All together – we captured nearly a 1000% gain on CVNA – all in less than 2 trading days.
Freaking awesome.
That’s the power of using patience and building on a lotto trade for a massive gain.
The one thing I caution traders is once you capture that massive gain – there’s a temptation to get back in on a quick dip and try to ride it for more.
Don’t do it.
I can’t tell you the number of times I’ve made a big gain on an options trade only to give it all back by thinking it’ll keep going higher.
Once I get the move into all-time highs, I close the trade and avoid trading that name for the rest of the day (usually).
Here’s what a few Daily Profits Live members had to say about the trade.
Carvana has the potential to keep running, so I’ll be looking to position via spreads in this week and next week in Daily Profits Live.
SPONSORED
Elon Musk’s Final Project REVEALED
It’s a secret project … bigger than Tesla … bigger than SpaceX … and bigger than Twitter.
Inside this warehouse in Memphis Tennessee…
Lies a new technology that is 100,000 times more powerful than Nvidia’s most advanced AI chip.
Nvidia’s CEO is even considering investing in this project directly.
Get the full details on Elon’s secret new AI project now.
Action Plan: If you want to see more charts I’m targeting, I’ll be joining CNBC/Fox Business superstar trader Jon Najarian on Wednesday for a special Unusually Bullish Charts: Technical Analysis Masterclass.
We’ll be going over our TOP 6 Favorite stock charts we’re watching.
The event is completely free.
SPONSORED
Crazy New Tech Stuns Scientists with World Record
A groundbreaking new tech just fully charged a laptop from 1% to 100%… in a world record NINE minutes.
Here’s why the tiny company that patented this tech could become the #1 stock by next year.
Monument Traders Alliance, LLC
You are receiving this email because you subscribed to Trade of the Day Wake-Up Watchlist.
To unsubscribe from Trade of the Day Wake-Up Watchlist, click here.
Questions? Check out our FAQs. Trying to reach us? Contact us here.
Please do not reply to this email as it goes to an unmonitored inbox.
To cancel by mail or for any other subscription issues, write us at:
Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201
North America: 800.507.1399 | International: +1.443.353.4977
Website | Privacy Policy
Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day.
© 2026 Monument Traders Alliance, LLC | All Rights Reserved
Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation.
Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.
Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.
REF: 000142349377
*Sponsored
Market Crux Announces Coverage On (TLSA) Is Starting
This Morning —Monday, January 26, 2026.
Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
(TLSA) Comes Backed By 7 Potential Catalysts (See Below)
Full Coverage Will Be Starting Very Shortly
Take A Close Look At (TLSA) While It’s Still Early…
January 26, 2026
First Look | See Why (TLSA) Just Jumped On To Our Early Morning Watchlist
Dear Reader,
The landscape of neurological medicine is shifting as a single biotech firm advances a delivery method that could change how we address some of the most stubborn diseases of the human brain.
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is currently at the center of this transition, utilizing a unique intranasal approach to treat neurodegenerative conditions that have long lacked effective solutions.
With a recent peer-reviewed publication and a surge in institutional support, this company is demanding the attention of anyone monitoring the future of biotechnology.
And that’s just some of the reasons why (TLSA) is topping our watchlist this morning—Monday, January 26, 2026.
Even at this early stage, (TLSA) is starting to stand out as one of the more closely followed names in neuro-immunology, thanks to a delivery approach that directly addresses the central nervous system.
And now, outside observers are beginning to put hard numbers around what that progress could mean.
Analyst Target Suggests Over 400% Upside Potential
One analyst has begun to take note of the progress at Tiziana Life Sciences, Ltd. (Nasdaq: TLSA).
Recently, Elemer Piros, PhD, an analyst with Lucid Capital Markets, published a bullish rating on the company. Dr. Piros set an $8 target on (TLSA), which suggests a 406% potential upside from its recent price range of $1.58.
This valuation is largely driven by the potential of the Foralumab platform and its applicability across a potential $33B market.
The analyst community often looks forde-risking events, and the recent peer-reviewed data for SPMS is considered a major milestone. As the company moves toward Phase 2 results in both MS and Alzheimer’s, the potential for upward revisions in valuation remains high, especially if the safety profile continues to hold up in larger patient populations.
The Tiziana Approach to Neuro-Immunology
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is a clinical-stage biotechnology company headquartered in London and New York, dedicated to developingtransformative therapies that leverage the body’s own immune system. The company’s primary focus revolves around its proprietary platform for the intranasal delivery of monoclonal antibodies.
Unlike traditional intravenous methods, this nasal-to-brain route is designed to bypass the blood-brain barrier, potentially allowing for localized therapeutic effects in the central nervous system while minimizing systemic side effects.
The company operates in the high-stakesneuroscience market, specifically targeting Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer’s disease, and Amyotrophic Lateral Sclerosis (ALS).
What makes (TLSA) distinctive is its lead candidate, Foralumab, which is the only entirely human anti-CD3 monoclonal antibody in clinical development.
By modulating T-cell responses and reducing neuroinflammation, (TLSA) aims to provide a new standard of care for patients who have exhausted traditional options.
Founded in 1998, the company has spent decades refining its approach toimmunotherapy. Its lean and virtual research model allows it to focus capital on high-value clinical activities rather than heavy overhead. This strategic structure has enabled TLSA to maintain a robust pipeline while advancing multiple orphan and large-market indications simultaneously.
The Scientific Foundation: Intranasal Foralumab
At the heart of Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is the scientific conviction that neuroinflammation is a primary driver of disease progression in the brain. Foralumab works by binding to the T-cell receptor complex, specifically the CD3 epsilon subunit. When administered through the nasal cavity, the therapy is designed to stimulateregulatory T cells (Tregs) in the cervical lymph nodes.
These “calming” cells then migrate to the brain, where they work to dampen the activity of microglia—the immune cells of the central nervous system that, when overactive, cause tissue damage in MS and Alzheimer’s patients.
This mechanism of action is a radical departure from traditional treatments. Most current MS therapies focus on systemic immunosuppression, which can leave patients vulnerable to infections.
In contrast, (TLSA) focuses on local modulation. By harnessing the body’s natural regulatory pathways, the company hopes to restore homeostasis in the brain without compromising the rest of the immune system.
Clinical Momentum and Market Positioning
The core thesis for Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) rests on its recent clinical validation and its unique position in the neuro-immunology sector.
On January 20, 2026, the company announced the peer-reviewed publicationof clinical study results for intranasal Foralumab, which showed signs of stabilizing disease progression and reducing microglial activation in patients with na-SPMS.
This publication in a respected medical journal provides a layer of scientific credibility that is essential for biotechnology firms approaching late-stage trials.
The market potential for (TLSA) is substantial, as the global Multiple Sclerosis market is projected to be worth approximately $16.8B in 2026. Specifically, the non-active Secondary Progressive Multiple Sclerosis (na-SPMS) population represents a significant segment of patients—estimated at roughly 30% to 40% of all MS cases—who currently have no FDA-approved treatments.
By positioning Foralumab as a potential first-in-class therapy for this group, (TLSA) is entering an area with minimal direct competition and high demand.
The company is also moving aggressively into Alzheimer’s disease, having already dosed the first patient in a Phase 2 trial.
With the global Alzheimer’s market projected to grow over 300% from around $7.7B in 2026 to over $33.6B by 2034, a successful inflammation-based therapy could represent a massive therapeutic class.
Unlike treatments focused strictly on amyloid plaque removal, TLSA is targeting the neuroinflammation that often persists even after plaques are cleared.
This rapid market expansion, driven by a global aging population, suggests that even a small share of the Alzheimer’s market could be transformative for a clinical-stage firm.
Operational achievements have been matched by a bolstered balance sheet. In January 2026, (TLSA) closed an oversubscribed $8.8M registered direct offering, following a previous announcement of an offering up to $17.6M. This capital infusion is intended to fund the continued Phase 2a clinical trial of Foralumab.
Furthermore, the Executive Chairmanrecently increased his personal stake in the company, signaling strong internal confidence in the firm’s trajectory.
The company currently maintains a market capitalization of approximately $174M, with recent analyst notes highlighting that the current valuation may not fully reflect the potential of itsmulti-indication pipeline. With recent funding secured, (TLSA) has extended its runway to meet several high-impact data readouts expected throughout 2026.
The management team at TLSA consists of seasoned veterans from major pharmaceutical backgrounds. Executive Chairman Gabriele Cerrone has a history of founding and scaling successful biotech ventures, including companies later acquired by major players like Bristol Myers Squibb.
This level of experience is vital for navigating the complex regulatory and commercial hurdles of the FDA approval process.
Their presence was felt during the 9th Annual Neuroscience Innovation Forumheld during the J.P. Morgan Healthcare Conference week in San Francisco. This platform allowed the company to showcase its pipeline to global institutional observers and potential strategic partners. Engaging with the broader biotech community at such a critical venue underscores the company’s commitment to transparency and clinical progress.
Beyond MS: A Versatile Pipeline
While MS and Alzheimer’s are the leading programs, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is developing a platform, not just a single application. The company has clinical assets targeting ALS, a devastating condition with few viable treatments. Preclinical data suggests that the same Treg stimulation seen in MS could help slow the motor neuron degradation characteristic of ALS.
Additionally, the company owns rights toMilciclib (TZLS-201), an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs). Milciclib has already shown safety and tolerability in over 300 patients across Phase 1 and 2 trials for advanced solid cancers. By maintaining a diversified portfolio that includes bothoncology and neurodegenerative programs, (TLSA) mitigates the risk inherent in single-program biotech firms.
The company’s TZLS-501 program also explores the use of anti-interleukin-6 receptor (anti-IL6R) monoclonal antibodies. This asset is being explored for its potential to treat lung inflammation, demonstrating the breadth of the company’s intellectual property portfolio. The ability to pivot this technology to various inflammatory sites makes (TLSA)a versatile player in the immunotherapy space.
7 Reasons Why (TLSA) is Topping Our Watchlist This Morning
—Monday, January 26, 2026…
1. Analyst Target: With an $8 targetfrom Lucid Capital Markets, (TLSA) is framed as having over 400% upside potential based on its recent range.
2. Chart History: Around this time last year, (TLSA) showed sharp volatility with an approximate 300% move in under 6 months, from around $0.65 to $2.60.
3. Peer Validation: A recent peer-reviewed publication of intranasal Foralumab results gives (TLSA)independent scientific support for its core approach.
4. Oversubscribed Funding: Anoversubscribed $8.8M registered direct offering in January 2026 provides (TLSA)added liquidity to pursue upcoming clinical milestones.
5. Insider Confidence: A recent increase in the Executive Chairman’s personal stake signals internal confidence at (TLSA) from someone closest to the program.
6. Clinical Momentum: Movement toward Phase 2 results in MS and Alzheimer’s keeps (TLSA) positioned around multiple 2026 data readouts tied to markets cited as roughly $16.8B for MS and about $33B for Alzheimer’s.
7. High-Profile Visibility: Participation during J.P. Morgan Healthcare Conference week in San Francisco helped place (TLSA) in front of institutional observers and potential partners.
Take A Close Look At (TLSA) While It’s Still Early…
When you put the pieces together, (TLSA) checks several boxes that serious market watchers tend to prioritize: an analyst target that suggests over 400% upside potential, a demonstrated history of sharp swings, and a peer-reviewed publication supporting its intranasal Foralumab results.
Add in fresh capital from an oversubscribed $8.8M raise, an Executive Chairman increasing his personal stake, and ongoing Phase 2 momentum in both MS and Alzheimer’s—and you can see why attention is building.
The fact that (TLSA) also showed up during J.P. Morgan Healthcare Conference week only reinforces that it’s on more radar screens than it was before.
We have all eyes on (TLSA) this morning.
Take a close look at (TLSA) while it’s still early.
Also, keep a lookout for my next update, it could be on its way to you before the bell rings.
Sincerely,
Gary Silver
Managing Editor,
Market Crux
MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, MC is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 01/25/2026 and ending on 01/26/2026 to publicly disseminate information about (TLSA:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid twenty one thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Headline Media LLC, TD Media LLC and their member own shares of (TLSA:US).
Please see important disclosure information here: https://marketcrux.com/disclosure/tlsa-XdMLI/#detailsHeadline Media7901 4th Street NSuite 300St. Petersburg, FL 33702UnsubscribeUpdate Profile | Constant Contact Data NoticeSent by gary@marketcrux.net
RJ Hamster